Phase 2 Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Sorafenib in Combination With Irinotecan
Phase of Trial: Phase II
Latest Information Update: 17 Feb 2018
At a glance
- Drugs Irinotecan (Primary) ; Sorafenib (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- 14 Feb 2017 Planned End Date changed from 1 Feb 2020 to 29 Feb 2020.
- 14 Feb 2017 Planned primary completion date changed from 1 Jan 2020 to 31 Jan 2020.
- 12 Aug 2016 Status changed from not yet recruiting to recruiting.